INTENSITY THERAPEUTICS, INC.
INTS evidence brief
What we can confirm
- Market Cap:
- $13.1M
What it means
What to watch
Prepared research question
What matters most for INTS—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · INTS
INTENSITY THERAPEUTICS, INC. (INTS) is a late-stage clinical biotechnology company developing intratumoral cancer therapies, primarily its lead candidate INT230-6, which is being evaluated in Phase 3 trials for soft tissue sarcoma and other cancers.
Key risk: No revenue and cash burn
Market Cap
$13.1M
Cash Runway
—
Lead Asset
—
Next Catalyst
—
Financial data as of Jun 30, 2026.
INTENSITY THERAPEUTICS, INC. (INTS) is a late-stage clinical biotechnology company developing intratumoral cancer therapies, primarily its lead candidate INT230-6, which is being evaluated in Phase 3 trials for soft tissue sarcoma and other cancers.
- Lead product candidate INT230-6 is a fixed-ratio combination of cisplatin, vinblastine sulfate, and the amphiphilic molecule SHAO, delivered via intratumoral injection [sec_mda · as of 2026-08-11].
- INT230-6 is in a Phase 3 study (INVINCIBLE-3) for locally recurrent, inoperable, or metastatic soft tissue sarcomas [catalyst].
- As of June 30, 2026, the company reported cash and equivalents of $9.5 million and a net loss of $3.0 million [latest reported financials].
- The company has incurred net losses since inception and expects to continue incurring losses as it advances R&D and clinical trials [sec_mda · as of 2026-08-11].
- INT230-6 is being studied in combination with Merck's Keytruda and BMS's Yervoy under collaboration agreements [pipeline].
What works
- INT230-6 uses a proprietary SHAO amphiphilic molecule to disperse cytotoxic agents within tumors, potentially improving efficacy and reducing systemic toxicity [sec_mda · as of 2026-08-11].
- The company has secured collaborations with major pharmaceutical partners including Merck and Bristol Myers Squibb for combination studies [pipeline].
- Research has undergone peer review and been published in high-impact journals such as OncoImmunology and The Lancet's eBioMedicine [sec_mda · as of 2026-08-11].
What to weigh
- The company has not generated any revenue from product sales and has incurred significant operating losses since inception [sec_mda · as of 2026-08-11].
- Cash and equivalents decreased from $10.2 million as of March 31, 2026 to $9.5 million as of June 30, 2026, indicating a cash burn rate that may require additional financing [sec_mda · as of 2026-05-07] [latest reported financials].
- The company expects R&D and G&A costs to continue increasing significantly, including costs for clinical trials, manufacturing, and public company operations [sec_mda · as of 2026-08-11].
From the filings
Quoted directly from source documents.
INT230-6 composition and mechanism
“Our lead product candidate, INT230-6, is primarily comprised of three components: (i) cisplatin, a proven anti-cancer cytotoxic agent, (ii) vinblastine sulfate, also a proven anti-cancer cytotoxic agent, and (iii) an amphiphilic molecule ("SHAO") which enables the two cytotoxic agents to disperse through a tumor and diffuse into cancer cells following a direct intratumoral injection.”
SEC MD&A · August 11, 2026
Cash position as of June 30, 2026
“As of June 30, 2026, we had approximately $9.5 million of cash and cash equivalents.”
SEC MD&A · August 11, 2026
No revenue from product sales and net losses
“Since our inception, we have not generated any revenue from product sales and have incurred significant operating losses.”
SEC MD&A · August 11, 2026
Phase 3 trial for soft tissue sarcoma
“A Multicenter, Randomized, Phase 3 Study to Assess the Efficacy and Safety of INtratumorally Administered INT230-6 (SHAO, VINblastine, CIsplatin) Compared With US Standard of Care in Adults With Locally Recurrent, InoperaBLE, or Metastatic Soft Tissue Sarcomas (INVINCIBLE-3)”
Catalysts
Catalyst timeline
- 2024-06-28 · Phase 3 start for INVINCIBLE-3 (soft tissue sarcoma) — A multicenter, randomized Phase 3 study comparing INT230-6 plus SOC versus SOC alone in adults with locally recurrent, inoperable, or metastatic soft tissue sarcomas.
Risks & what to watch (4)›
Key risks
- No revenue and cash burn — No product revenue; cash fell from $10.2M (Mar 2026) to $9.5M (Jun 2026); may need additional financing [sec_mda].
- Clinical trial execution risk — Phase 3 INVINCIBLE-3 trial enrollment may face delays; company added resources to accelerate [sec_mda · as of 2026-08-11].
- Dependence on single lead candidate — INT230-6 is the sole lead candidate; pipeline lacks diversified assets [pipeline].
- Regulatory and competitive landscape — INT230-6 uses generic drugs; must differentiate from SOC with median OS 11-15 months in sarcoma [pipeline].
What to watch
- Enrollment progress and completion of the Phase 3 INVINCIBLE-3 trial for soft tissue sarcoma, targeted by end of 2027 [sec_mda · as of 2026-08-11].
- Cash runway and potential need for additional financing given the $9.5M cash position and ongoing net losses [latest reported financials].
- Results from the INVINCIBLE-4 Switzerland study evaluating pCR rates with INT230-6 plus standard of care [news · 2026-07-15].
- Any updates on regulatory interactions or NDA submission for INT230-6 [pipeline].
Sources: Catalysts · News · Pipeline · SEC MD&A · Generated October 4, 2026 · How we verify sources →
Run INTENSITY THERAPEUTICS, INC. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available INTENSITY THERAPEUTICS, INC. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
12
Total value held
$830K
| Holder | Shares | Value |
|---|---|---|
| geode capital management, llc | 26,019 | $153K |
| sapient capital llc | 26,006 | $153K |
| nano cap new millennium growth fund l p | 25,000 | $147K |
| rothschild wealth llc | 23,294 | $137K |
| vanguard capital management llc | 16,841 | $99K |
| mesirow financial investment management, inc. | 14,118 | $83K |
| vanguard fiduciary trust co | 9,121 | $54K |
| osaic holdings, inc. | 200 | $1K |
| wells fargo & company/mn | 200 | $1K |
| ubs group ag | 192 | $1K |
Showing top 10 of 12 institutional holders of INTENSITY THERAPEUTICS, INC.. Open the full 13F history after sign-in.
Short Interest
as of Apr 21, 2026- % of float
- 2.5%
- Days to cover
- 2.2
- Shares short
- 61,082
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
INTS short interestGovernance
Frequently asked questions
What is the AI investment thesis for INTENSITY THERAPEUTICS, INC.?
INTENSITY THERAPEUTICS, INC. (INTS) is a late-stage clinical biotechnology company developing intratumoral cancer therapies, primarily its lead candidate INT230-6, which is being evaluated in Phase 3 trials for soft tissue sarcoma and other cancers.
Who is the CEO of INTENSITY THERAPEUTICS, INC.?
Mr. Lewis H. Bender M.A., M.B.A., M.S. is the chief executive officer of INTENSITY THERAPEUTICS, INC. (INTS).
Where is INTENSITY THERAPEUTICS, INC. headquartered?
INTENSITY THERAPEUTICS, INC. (INTS) is headquartered in Shelton, CT, United States.
What therapeutic areas does INTENSITY THERAPEUTICS, INC. focus on?
INTENSITY THERAPEUTICS, INC. develops therapies across Oncology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.